April 2018
-
HIV Serostatus and Having Access to a Physician for Regular Hepatitis C
Virus Care Among People Who Inject Drugs.
Beaulieu T, Hayashi K, Milloy MJ,
et alJ
Acquir Immune Defic Syndr. 2018 May
1;78(1):93-98.
-
The Impact of Direct-Acting Antiviral Agents on Liver and Kidney
Transplant Costs and Outcomes.
Axelrod DA, Schnitzler MA, Alhamad T,
et al
Am J Transplant.
2018 Apr 27.
-
HCV core antigen comes of age: a new opportunity for the
diagnosis of hepatitis C virus infection.
Galli C, Julicher P, Plebani M.Clin
Chem Lab Med. 2018 Apr 27.
-
Integrated Care for the Use of Direct-acting Antivirals in Patients With
Chronic Hepatitis C and Substance Use Disorder.
Trabut JB, Barrault C, Charlot H,
et alJ
Addict Med. 2018 Apr
26.
-
Real-Time Elastography: Noninvasive Diagnostic Tool in the
Evaluation of Liver Stiffness in Patients with Chronic Viral Hepatitis,
Correlation with Histological Examination.
Ippolito D, Schiavone V,
Talei Franzesi CR,
et alDig
Dis. 2018 Apr 26:
-
Generic sofosbuvir based direct-acting antivirals in hepatitis C
virus infected patients with chronic kidney disease.
Sharma MK, Nayak SL, Gupta E,et
al
Liver Int. 2018
Apr 20.
-
FULL::-TEXT ARTICLE
CD81 Receptor Regions
outside the Large Extracellular Loop Determine Hepatitis C Virus Entry into
Hepatoma Cells.
Banse P, Moeller R, Bruening J, et al
Viruses. 2018 Apr
20;10(4).
-
Uptake of and Expenditure on Direct-Acting Antiviral Agents
for Hepatitis C Treatment in Australia.
de Graaff B, Yee KC, Clarke
P, Palmer A
Appl
Health Econ Health Policy.
2018 Apr 19.
-
Glecaprevir/Pibrentasvir Treatment in Liver or Kidney
Transplant Patients With Hepatitis C Virus Infection.
Reau N, Kwo PY, Rhee S.,et al
Hepatology.
2018 Apr 19.
-
Hepatitis C care continuum and associated barriers among people
who inject drugs in Chennai, India.
Patel EU, Solomon SS, Mcfall AM, et al
Int J Drug Policy. 2018
Apr 18
-
Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks
for the treatment of HCV genotype 4 infection: results from a randomised
phase III study in Egypt.
Shiha G, Esmat G, Hassany M, Gut.
2018 Apr 17.
-
Generic velpatasvir plus sofosbuvir for hepatitis C virus infection in patients
with or without human immunodeficiency virus coinfection.
Liu CH, Sun HY, Liu CJ, et al
Aliment Pharmacol Ther.
2018 Apr 17.
-
Real-world use of elbasvir-grazoprevir in patients with chronic hepatitis C:
retrospective analyses from the TRIO network.
Flamm SL, Bacon B, Curry MP,
et al
Aliment
Pharmacol Ther. 2018 Apr 17
-
Sofosbuvir plus Daclatasvir with or without ribavirin for
treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G, Soliman R, ElBasiony M,
et al
Hepatol
Int. 2018 Apr 16.
-
Unexpected Replication Boost by Simeprevir for Simeprevir-resistant Variants in
Genotype 1a Hepatitis C Virus.
Murai K, Shimakami T, Welsch C, et al
Antimicrob Agents Chemother.
2018 Apr 16.
-
Sofosbuvir plus Daclatasvir with or without ribavirin for
treatment of chronic HCV genotype 4 patients: real-life experience.
Shiha G, Soliman R, ElBasiony M,
et al
Hepatol Int. 2018 Apr
16.
-
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the
Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe
Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Sperl J, Kreidlova M, Merta D, et alKidney
Blood Press Res. 2018 Apr
13;43(2):594-605.
-
Extra hepatic cancers are the leading cause of death in
cirrhotic patients achieving HBV control or HCV eradication.
Allaire M, Nahon P, Layese R, et alHepatology.
2018 Apr 16.
-
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and
dasabuvir is highly effective in people with recent HCV genotype 1
infection.
Martinello M, Bhagani S, Gane E, et al
J
Viral Hepat. 2018 Apr 16
-
A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis
and Implications.
Aston PJ.Viruses.
2018 Apr 13;10(4).
-
Highlights of the Structure Activity Relationships of
Benzimidazole Linked Pyrrolidines Leading to the Discovery of the HCV NS5A
Inhibitor Pibrentasvir (ABT-530).
Wagner R, Randolph JT, Patel SV, et alJ
Med Chem. 2018 Apr 13
-
A New Model for the Dynamics of Hepatitis C Infection: Derivation, Analysis
and Implications.
Aston PJ.Viruses.
2018 Apr 13;10
-
Incidence of Hepatocellular Carcinoma in Patients with HCV-associated
Cirrhosis Treated with Direct-Acting Antiviral Agents.
Calvaruso V, Cabibbo G, Cacciola I, et al
Gastroenterology.
2018 Apr 12
-
Hepatitis C virus status awareness and test results confirmation
among people who inject drugs in Ukraine.
Iakunchykova
O, Meteliuk A, Zelenev A,
et al
Int J Drug Policy.
2018 Apr 11;57:11
-
FULL-TEXT ARTICLE
Estimated hepatitis C prevalence and key population sizes in San Francisco:
A foundation for elimination.
Facente SN, Grebe E, Burk K, et a lPLoS
One. 2018 Apr
11;13(4):e0195575.
-
Hepatitis C virus status awareness and test results
confirmation among people who inject drugs in Ukraine.
Iakunchykova O,
Meteliuk A, Zelenev A,
et al
Int J Drug Policy.
2018 Apr 11;57:11
-
FULL-TEXT ARTICLE
Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with
decompensated cirrhosis.
Pérez-Latorre L, Sánchez-Conde M, MirallesBMC
Infect Dis. 2018 Apr 11;18(1):
-
FULL-TEXT ARTICLE
A
case report of sofosbuvir and daclatasvir to treat a patient with acute
hepatitis C virus genotype 2 monoinfection.
Li C, Hu J.Medicine
(Baltimore). 2018
Apr;97(15):e0416.
-
Investigation of anti-Hepatitis C virus, sofosbuvir and
daclatasvir, in pure form, human plasma and human urine using micellar
monolithic HPLC-UV method and application to pharmacokinetic study.
Zidan DW, Hassan WS, Elmasry
MS, Shalaby AA.
J Chromatogr B Analyt Technol Biomed Life Sci.
2018 Apr 7
-
FULL-TEXT ARTICLE
Lectin microarray
and mass spectrometric analysis of hepatitis C proteins reveals N-linked
glycosylation.
Guo Y, Yu H, Zhong Y, et alMedicine
(Baltimore). 2018
Apr;97(15):e0208.
-
Should Organs from Hepatitis C Positive Donors be used in
Hepatitis C Negative Recipients for Liver Transplantation?
Selzner N, Berenguer M.Liver
Transpl. 2018 Apr 6.
-
Clinical evaluation of efficacy, tolerability and pharmacokinetics of
yimitasvir phosphate in patients infected with hepatitis C virus.
Zhang H, Zhu X, Li Q, Lou J,
et al
J Pharm Pharmacol. 2018
Apr 6
-
Feasibility of all-oral anti-HCV treatment during DHAP chemotherapy
and autologous stem cell transplantation for T-cell lymphoma
Rossotti R, Rusconi C, Baiguera C,
et al
New Microbiol. 2018 Apr 5;41(1).
-
Interferon-free treatment choice according to baseline RASs
leads to high SVR rates in HCV genotype 1 infected patients.
Peiffer KH, Vermehren J,
Kuhnhenn L, et al.
J Infect Chemother. 2018 Apr 5.
-
A sofosbuvir-based quadruple regimen is highly effective in HCV type
4-infected Egyptian patients with DAA treatment failure.
Abdel-Moneim A, Aboud A, Abdel-Gabbar M,
et alJ
Hepatol. 2018 Apr 3.
-
The role of IDO, IL-10 and TGF-β in the HCV-associated
chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma.
Yang R, Gao N, Chang Q,
et alJ
Med Virol. 2018
Apr 3.
-
Significance of detectable HCV RNA below the limit of
quantification in patients treated with DAAs using standard and
ultrasensitive protocols.
Visco-Comandini U, Lapa D,
J Med Virol.
2018 Apr 3.
-
FULL-TEXT ARTICLE
Increasing
Access to Hepatitis C Virus Medications: A
Program Model Using Patient Navigators and
Specialty Pharmacy to Obtain Prior
Authorization Approval.
Vu TM, Toribio W, Riazi F, et al
J Manag Care Spec Pharm.
2018 Apr;24(4):329-333.
-
Direct-acting antiviral drugs for chronic
hepatitis C and risk of major
vascular events: a systematic review.
Tamborini Permunian E, Gervaso L,
et alIntern
Emerg Med.
2018 Apr 2
-
Cost-effectiveness of novel treatment of hepatitis C virus in
Lebanese patients.
Nasser SC, Mansour H, Abi Nader T, Metni M.
Int J Clin Pharm.
2018 Apr 2.
-
Implementation of hepatitis C cure in Australia: one year on.
Richmond JA, Wallace J.
J
Virus Erad. 2018 Apr 1;4(2):115-117.
-
FULL-TEXT ARTICLE
Bullous pemphigoid
associated with chronic hepatitis C virus infection in a hepatitis B virus
endemic area: A case report.[South Korea]
Jang H, Jin YJ, Yoon CH, Kim CW, Kim L.Medicine
(Baltimore). 2018
Apr;97(15):e0377.
-
Prognostic value of viral eradication for major adverse
cardiovascular events in hepatitis C cirrhotic patients.
Cacoub P, Nahon P, Layese R, Blaise L,
et alAm
Heart J. 2018 Apr;198:4-17
-
Hepatitis C Virus Eradication in Kidney Transplant Recipients: A
Single-Center Experience in Portugal.
Weigert A, Querido S, Carvalho L,
Transplant Proc.
2018 Apr;50(3):743-745
|
|
|
Journal
Papers, Abstracts, and Commentaries
|
|
A
New Model for the Dynamics of Hepatitis C Infection: Derivation,
Analysis and Implications.
Aston PJ.
Viruses. 2018 Apr
13;10(4).
Abstract
Heading Toward the Elimination of Hepatitis C Virus.
Kershenobich D, Torre-Delgadillo A, Aguilar-Valenzuela LM.
Rev Invest Clin.
2018;70(1):29-31.
Abstract
s global elimination of HCV realistic?
Calvaruso V, Petta S, Craxì A.
Liver Int. 2018
Feb;38 Suppl 1:40-46. d
Abstract
Genetic Analysis of Serum-derived HCV Defective Genomes
Revealed Novel Viral Cis-Elements for Virus Replication and Assembly.
Li Q, Tong Y, Xu Ym et
al
J Virol. 2018
Jan 24
Abstract
FULL-TEXT
ARTICLE
The
global origins of resistance-associated variants in the non-structural
proteins 5A and 5B of the hepatitis C virus.
Jones BR, Howe AYM, Harrigan PR, Joy JB.
Virus
Evol. 2018 Jan
16;4(1):vex041
Paper
HLA-B, HLA-C and KIR improve the predictive value of
IFNL3 for Hepatitis C spontaneous clearance.
Frias M, Rivero-Juárez A, Rodriguez-Cano D,
et a;
Sci
Rep. 2018 Jan 12;8(1):65
Abstract
Understanding and addressing hepatitis C reinfection in the oral direct
acting antiviral era.
Falade-Nwulia O, Sulkowski MS,
et al
J Viral Hepat.
2018 Jan 6.
Abstract
Hepatitis C virus: Enslavement of host factors.
Sharma
G, Raheja H, Das S .
IUBMB
Life. 2018 Jan;70(1):41-49
Abstract
FULL-TEXT ARTICLE
Probing the antigenicity of hepatitis C virus envelope glycoprotein
complex by high-throughput mutagenesis
Gopal R, Jackson K, Tzarum N, et al
PLoS Pathog.
2017 Dec 18;13(12):e1006735.
Paper
HCV and the Impact of Host Genetics.
Cook L.
J Mol Diagn. 2017
Sep 27
Abstract
FULL-TEXT ARTICLE
Factors
associated with hepatitis C virus RNA levels in early chronic infection:
the InC3 study
Hajarizadeh B1, Grady B2, Page K3,et al
J Viral Hepat. 2015 Sep;22(9):708
Paper
Dual Roles of Two Isoforms of Autophagy-related Gene ATG10 in HCV-Subgenomic
replicon Mediated Autophagy Flux and Innate Immunity.
Zhao Q, Hu ZY, Zhang JP,
et al
Sci Rep. 2017 Sep
12;7(1):11250
Abstract
Nuclear Magnetic Resonance Study of RNA Structures at the
3'-End of the Hepatitis C Virus Genome.
Kranawetter C, Brady S, Sun L, et
al
Biochemistry. 2017
Sep 6
Abstract
Engaging hepatitis C infected patients in
cost-effectiveness analyses: A literature review.
Mattingly TJ 2nd, Perfetto EM, Johnson S.
Hepatology.
2017 Aug 23.
Abstract
FULL-TEXT ARTICLE
Hepatitis C Virus-Induced Autophagy and Host Innate Immune Response.
Chan ST, Ou JJ.
Viruses.
2017 Aug 12;9(8).
Paper
HCV plays with fire and yet avoids getting burned. A review for
clinicians on processing bodies and stress granules.
Fernández-Carrillo C, Pérez-Vilaró G, Díez J, Pérez-Del-Pulgar S
Liver Int.
2017
Abstract
Genetic variants underlying vitamin D metabolism and VDR-TGFβ-1-SMAD3
interaction may impact on HCV progression: a study based on dbGaP data
from the HALT-C study.
de Azevedo LA, Matte U, da Silveira TR, Álvares-da-Silva MR.
J Hum
Genet. 2017 Jul 13.
Abstract
Research priorities to achieve universal access to hepatitis C prevention,
management and direct-acting antiviral treatment among people who inject
drugs.
Grebely J, Bruneau J, Lazarus JV, et al
Int J Drug Policy.
2017 Jul 3.
Abstract
Changing trends in complications of chronic hepatitis C.
Lu M, Li J, Rupp LB, et al
Liver
Int. 2017 Jun 21.
Abstract
NS3
protease resistance-associated substitutions in liver tissue and plasma
samples from patients infected by hepatitis C virus genotype 1A or 1B
Morsica G, Andolina A, Merli M, et al
Arch
Virol. 2017 Apr
Abstract
Relationship between Hepatitis C Virus Infection and Iron
Overload.
Zou DM, Sun WL.
Chin Med J (Engl).
2017 Apr 5;130(7):866-871.
Abstract
Hepatitis C virus infection.
Manns MP, Buti M, Gane E,
et al
Nat Rev Dis Primers. 2017
Mar 2;3:17006.
Abstract
Conflict of Interest in Seminal Hepatitis C Virus and
Cholesterol Management Guidelines.
Jefferson AA, Pearson SD.
JAMA Intern Med.
2017 Jan 17
Abstract
Scaling-up HCV treatment to achieve WHO targets by 2030.
Cooke G.
Trop Med Int Health. 2017
Jan 10.
Abstract
Genotype 3 Infection: The Last Stand of Hepatitis C Virus.
Chan A, Patel K, Naggie S
Drugs. 2017 Jan 10.
Abstract
Intrahepatic angiopoietin-2 correlates with Chronic Hepatitis C
progression and is induced in HCV replicon systems.
Hernández-Bartolomé Á, López-Rodríguez R,
et al
Liver Int.
2016 Dec 27.
Abstract
FULL-TEXT ARTICLE (link to download article)
Translation initiation by
the hepatitis C virus IRES requires eIF1A and ribosomal complex remodeling.
Jaafar ZA, Oguro A, Nakamura Y, Kieft JS.
Elife. 2016 Dec 23;
Paper
FULL-TEXT ARTICLE
Cynaropicrin: A
Comprehensive Research Review and Therapeutic Potential As an Anti-Hepatitis C
Virus Agent.
Elsebai MF, Mocan A, Atanasov AG.
Front Pharmacol.
2016 Dec 8;7:472
Paper
FULL-TEXT ARTICLE
Apolipoprotein
B100 is required for hepatitis C infectivity and Mipomersen inhibits hepatitis
C.
Schaefer EA, Meixiong J, Mark C, et al
World J Gastroenterol.
2016 Dec 7;22(45):9954-9965. d
Paper
Hepatitis C genotype 3 disease.
Kattakuzhy S, Levy R, Rosenthal E,
et al
Hepatol Int. 2016
Nov;10(6):861-870.
Abstract
FULL-TEXT ARTICLE
Elevation of Alanine Aminotransferase Activity Occurs after Activation of
the Cell-Death Signaling Initiated by Pattern-Recognition Receptors but
before Activation of Cytolytic Effectors in NK or CD8+ T Cells in the Liver
During Acute HCV Infection.
Choi YH, Jin N, Kelly F, et al
PLoS One. 2016 Oct
27;11(10):e0165533.
Paper
Update on Hepatitis C treatment: Systematic review of clinical trials.
Jhaveri M, Procaccini N, Kowdley KV.
Minerva Gastroenterol Dietol.
2016 Oct 21.
Abstract
Innate immunity against hepatitis C virus.
Xu Y, Zhong
J.
Curr Opin
Immunol. 2016 Oct;42:98-104
Abstract |
I mpact
of caffeine in hepatitis C virus infection: a systematic review and
meta-analysis.
Wijarnpreecha K, Thongprayoon C, Ungprasert P.
Eur J Gastroenterol Hepatol. 2016
Sep 26
Abstract
Hepatitis C virus and human immunodeficiency virus transmission
routes: Differences and similarities
Cainelli F.
World J Hepatol. 2013 May
27;5(5):234-6.
Abstract
FULL-TEXT ARTICLE
Hepatitis C virus, cholesterol
and lipoproteins - impact for the viral life cycle and pathogenesis of liver
disease
Felmlee DJ, Hafirassou ML, Lefevre M, et al
Viruses. 2013 May
23;5(5):1292-324.
Paper
Late autoimmune hepatitis after hepatitis C therapy.
Efe C, Heurgué-Berlot A, Ozaslan E, et al
Eur J Gastroenterol Hepatol.
2013 Apr 26
Abstract
Patients with hepatitis C infection and normal liver function:
an evaluation of cognitive function.
Abrantes J, Torres DS, de Mello CE.
Postgrad Med J. 2013 Apr 26.
Abstract
|A
global view of hepatitis C: Physician knowledge, opinions, and perceived
barriers to care.
McGowan CE, Monis A, Bacon BR,
et al
Hepatology. 2013 Jan 12.
Abstract |
Pharmacogenomics of hepatitis C infections: personalizing
therapy.
Booth DR, Ahlenstiel G, George J.
Genome Med. 2012
Dec 26;4(12):99.
Abstract |
Vitamin A deficiency is associated with HCV chronic infection
and with unresponsiveness to interferon based antiviral therapy.
Bitetto D, Bortolotti N, Falleti E,
et al
Hepatology. 2012 Dec 5.
Abstract
HCV's days are numbered: next-generation direct-acting
antivirals and host-targeting agents.
Calle Serrano B, Manns MP
Antivir Ther.
2012;17(6 Pt B):1133-46
Abstract
Hepatitis C virus genotype 5: an orphan virus.
Antaki N, Abboud D, Antaki F,
Craxi A.
Antivir Ther.
2012 Oct 30.
Abstract
New perspectives in occult hepatitis C virus
infection.
Carreño V, Bartolomé J, Castillo I, Quiroga JA
World J Gastroenterol.
2012 Jun 21;18(23):2887-94.
Abstract
Fish to meat intake ratio and cooking oils are associated
with hepatitis C virus carriers with persistently normal alanine
aminotransferase levels.
Otsuka M, Uchida Y, Kawaguchi T, Taniguchi E,
et al;
Hepatol Res.
2012 Mar 29.
Abstract
|
Hepatitis C virus-specific cellular immune responses in
individuals with no evidence of infection.
Riviere Y, Montange T, Janvier G, Marnata C,
et al
Virol J.
2012 Mar 28;9(1):76.
Abstract |
|
|
Pharmacogenetics of hepatitis C.
Soriano V, Poveda E, Vispo E,
et al
J Antimicrob Chemother.
2011 Dec 22
Abstract |
Strong Correlation between Liver and Serum Levels of
Hepatitis C Virus Core Antigen and RNA in Chronically
Infected Patients.
Descamps V, Op de Beeck A, Plassart C, et al
J Clin Microbiol.
2011 Dec 7.
Abstract
FULL-TEXT ARTICLE
Recombination in hepatitis C virus.
González-Candelas F, López-Labrador FX, Bracho MA.
Viruses.
2011 Oct;3(10):2006-24.
Paper |
FULL-TEXT ARTICLE
Clinical implications of chemokines in acute and chronic
hepatitis C virus infection.
Kang W, Shin EC.
Yonsei Med J. 2011 Nov 1;52(6):871-8.
Abstract
|
FULL-TEXT
ARTICLE
Antibody V(h) Repertoire Differences between Resolving and
Chronically Evolving Hepatitis C Virus Infections.
Racanelli V, Brunetti C, De Re V, et al
PLoS One.
2011;6(9):e2560
Paper
|
All-cause and incremental per patient per year cost
associated with chronic hepatitis C virus and associated
liver complications in the United States: a managed care
perspective.
McAdam-Marx C, McGarry LJ,
et al
J Manag Care Pharm.
2011 Sep;17(7):531-46
Abstract
|
Low risk for hepatitis C seroconversion in
methadone maintenance treatment.
Peles E, Schreiber S, Rados V, Adelson M.
J Addict Med.
2011 Sep;5(3):214-20.
Abstract
|
Long-term follow-up among Danish transfusion recipients
identified in the national hepatitis C lookback.
Just SA, Grau K, Georgsen J, et al
Transfusion.
2011 Aug 29.
Abstract
|
Hot topic debate on HCV: The type of immunosuppression
matters.
Trotter JF.
Liver Transpl.
2011 Aug 17
Abstract
|
Economic Burden Associated With Patients Diagnosed With
Hepatitis C.
McCombs JS, Yuan Y, Shin J, Saab S.
Clin Ther.
2011 Aug 11.
Abstract |
Vitamin A deficiency in patients with hepatitis C
virus-related chronic liver disease.
Peres WA, Chaves GV, Gonçalves JC, Ramalho A, Coelho HS.
Br J Nutr.
2011 Jun 8:1-8.
Abstract |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Videos
|
| |
|
Polaris Symposium: Economic Impact of Eliminating
HCV |
Kirby Institute Symposium 2015 - Debate:
Global elimination of HCV is feasible in our lifetime
|
|
|
|
Journal Papers, Abstracts, and Commentaries
|
| |
FULL-TEXT ARTICLE
The Paradoxical Effects of Different Hepatitis C Viral Loads
on Host DNA Damage and Repair Abilities.
Wang SC, Lai KR, Li CY,. et al
PLoS One.
2017 Jan 4;12(1):e0164281.
Paper
Consolidation of molecular testing in clinical virology.
Scagnolari C, Turriziani O, Monteleone K,
Pierangeli A, Antonelli G.
Expert Rev Anti Infect Ther.
2016 Dec 22
Abstract
Low Pretreatment Acoustic Radiation Force Impulse Imaging (ARFI)
Values Predict Sustained Virological Response in Antiviral
Hepatitis C Virus (HCV) Therapy.
Zopf S, Rösch L, Konturek PC, et al
Med Sci Monit.
2016 Sep 30;22:3500-3505.
Abstract
Role of HCV-RNA decay and IP-10 levels after
48hours of standard HCV therapy as predictors of rapid
virological response.
Prinapori R,
Sticchi L, Alicino C, et al
Clin Res Hepatol Gastroenterol.
2015
Abstract
Anti-hepatitis C virus seropositivity is not
associated with metabolic syndrome irrespective of age,
gender and fibrosis.
Cheng YL, Wang YC,
Lan KH, et
al
Ann Hepatol. 2015
Mar-Apr 2015;14(2):181-189.
Abstract
Factors associated with hepatitis C virus RNA
levels in early chronic infection: the InC3
study.
Hajarizadeh B, Grady B, Page K, et al
J Viral Hepat. 2015 Jan 8
Abstract
The association of il28b genotype with the
histological features of chronic hepatitis C is
HCV genotype
dependent.
D'Ambrosio R, Aghemo A, De Francesco R, et al
Int J Mol Sci.
2014 Apr 25;15(5):7213-24
Abstract
FULL-TEXT
ARTICLE
How hepatitis C virus invades hepatocytes: The mystery of
viral entry.
Zhu YZ, Qian XJ, Zhao P, Qi ZT.
World J Gastroenterol.
2014 Apr 7;20(13):3457-3467
Paper
Estimating the likelihood of sustained
virological response in chronic hepatitis C therapy.
Mauss S, Hueppe D, John C, et al
J Viral Hepat.
2010 Sep 16.
Abstract |
Sustained virological response according to the type of early
virological response in HCV and HCV/HIV.
Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C.
Ann Hepatol.
2010 Jun 1;9(2):150-155.
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
| |
Natural history and management of hepatitis C: does
sex play a role?
Baden R, Rockstroh JK, Buti M.
J Infect Dis. 2014 Jul 15;209 Suppl
3:S81-5.
Abstract
Acute hepatitis C: clinical and laboratory diagnosis, course of
the disease, treatment.
Sagnelli E, Santantonio T, Coppola N,
et al
Infection.
2014 Mar 12..
Abstract
Epidemiology and natural history of HCV infection.
Hajarizadeh B, Grebely J, Dore GJ.
Nat Rev Gastroenterol Hepatol.
2013 Jul
Abstract
Lack of clinical and histological progression of chronic
hepatitis C in individuals with true persistently normal ALT: the result of a
17-year follow-up.
Nunnari G, Pinzone MR, Cacopardo
B.
J Viral Hepat. 2013
Apr;20(4):e131-7.
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
|
| |
|
FULL-TEXT ARTICLE
Increasing Access to Hepatitis C Virus Medications: A Program Model
Using Patient Navigators and Specialty Pharmacy to Obtain Prior
Authorization Approval.
Vu TM, Toribio W, Riazi F, et al
lJ
Manag Care Spec Pharm.
2018 Apr;24(4):329-333.
Paper
A clinician's guide to the cost and health benefits of
hepatitis C cure assessed from the individual patient perspective.
McEwan P, Selvapatt N, Brown A,
et al
Eur J Gastroenterol Hepatol.
2016 Nov 9.
.
Abstract
Adherence to treatment of chronic hepatitis C: from
interferon containing regimens to interferon and ribavirin free regimens.
Younossi ZM, Stepanova M, Henry L et al
Medicine
(Baltimore) . 2016 Jul;95(28):e4151
Abstract
FULL-TEXT ARTICLE
The common
sense model applied to hepatitis C: a qualitative analysis of the impact of
disease comparison and witnessed death on hepatitis C illness perception.
Safo SA, Batchelder A, Peyser D, Litwin A.
et al
Harm
Reduct J. 2015 Jun 20;12(1):20
Paper
|
"Hepatitis C treatment turned me around:" Psychological and
behavioral transformation related to hepatitis C treatment.
Batchelder AW, Peyser D, Nahvi S, et al
Drug Alcohol Depend.
2015 Jun 9.
Abstract
Physical, Social, and Psychological Consequences of Treatment
for Hepatitis C : A Community-Based Evaluation of Patient-Reported Outcomes.
Manos MM, Ho CK, Murphy RC,
Shvachko VA
Patient. 2013 Feb 1
Abstract |
|
|
Journal Papers, Abstracts, and Commentaries
|
 |
|
|
|
|
|
|
|
Home
Page
Documents identified with this icon are in Portable Document Format (PDF)
and require the
Adobe
Acrobat Reader